Section Arrow
GHRS.NASDAQ
- GH Research PLC
Quotes are at least 15-min delayed:2025/06/04 01:04 EDT
Last
 12.08
+0.52 (+4.50%)
Day High 
12.24 
Prev. Close
11.56 
1-M High
13.25 
Volume 
299.60K 
Bid
10.63
Ask
14.77
Day Low
10.96 
Open
11.38 
1-M Low
9.4557 
Market Cap 
717.05M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.83 
20-SMA 11.15 
50-SMA 10.53 
52-W High 20.5 
52-W Low
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.79/-1.29
Enterprise Value
717.41M
Balance Sheet
Book Value Per Share
5.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/04 01:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.